Comparative risk of serious psychiatric events with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus

Objective To compare the risk of serious psychiatric outcomes among patients with systemic lupus erythematosus initiating belimumab versus oral immunosuppressants. Methods We emulated a target trial using observational data from TriNetX electronic health records database to compare the risks of serious psychiatric events among patients with non-renal SLE initiating belimumab or an oral immunosuppressant (azathioprine, methotrexate, or mycophenolate). Propensity score overlap weighting was used to emulate randomization. The main outcomes were hospitalization for depression and suicide attempt or self-harm. In a per-protocol analysis, we used inverse probability of treatment weighting to adjust for adherence to assigned treatment. A secondary analysis assessed new-onset depression. Results We compared 2434 and 5644 initiators of belimumab and azathioprine, 2163 and 7224 initiators of belimumab and methotrexate, and 2431 and 6350 initiators of belimumab and mycophenolate, respectively. After weighting, baseline covariates were balanced across groups; 95% of patients were female and mean age was 44 years. Belimumab was not associated with an increased risk of hospitalization for depression compared with azathioprine, methotrexate, or mycophenolate. Suicide attempt or self-harm were rare. There was no difference in the risk of new-onset depression among patients without prior mood disorder. Conclusion Among patients with non-renal SLE, belimumab was not associated with increased risk of serious psychiatric events compared with commonly used oral immunosuppressants, supporting its safety in clinical practice.

Authors

Institutions

Publication Details

Journal
Lupus
Published
2026-11-14
DOI
https://doi.org/10.1177/09612033261509144
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative risk of serious psychiatric events with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus

Baijun Zhou, April M Jorge, Jacquelyn Nestor, Zhanara Altynbekova et al.
Lupus
Systemic Lupus Erythematosus Research
article

Comparative risk of serious psychiatric events with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus

Baijun Zhou, April M Jorge, Jacquelyn Nestor, Zhanara Altynbekova, Yuqing Zhang, Lingxiao Zhang, Hyon Choi, Haeun Lee
article en

Abstract

Objective To compare the risk of serious psychiatric outcomes among patients with systemic lupus erythematosus initiating belimumab versus oral immunosuppressants. Methods We emulated a target trial using observational data from TriNetX electronic health records database to compare the risks of serious psychiatric events among patients with non-renal SLE initiating belimumab or an oral immunosuppressant (azathioprine, methotrexate, or mycophenolate). Propensity score overlap weighting was used to emulate randomization. The main outcomes were hospitalization for depression and suicide attempt or self-harm. In a per-protocol analysis, we used inverse probability of treatment weighting to adjust for adherence to assigned treatment. A secondary analysis assessed new-onset depression. Results We compared 2434 and 5644 initiators of belimumab and azathioprine, 2163 and 7224 initiators of belimumab and methotrexate, and 2431 and 6350 initiators of belimumab and mycophenolate, respectively. After weighting, baseline covariates were balanced across groups; 95% of patients were female and mean age was 44 years. Belimumab was not associated with an increased risk of hospitalization for depression compared with azathioprine, methotrexate, or mycophenolate. Suicide attempt or self-harm were rare. There was no difference in the risk of new-onset depression among patients without prior mood disorder. Conclusion Among patients with non-renal SLE, belimumab was not associated with increased risk of serious psychiatric events compared with commonly used oral immunosuppressants, supporting its safety in clinical practice.

Lupus
Harvard University (US), Salem Hospital (US), Massachusetts General Hospital (US)
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon